Rhythm Biosciences (FRA:0RY) Payments of Debt: €-0.59 Mil (TTM As of Dec. 2025)


FRA:0RY Rhythm Biosciences Ltd FRA:0RY
31 GF Score
Price €0.05
! 5 Warning Signs
View Full Analysis

What is Rhythm Biosciences Payments of Debt?

Rhythm Biosciences FRA:0RY +0.96% 31 Payments of Debt is €-0.59 Mil as of Dec. 2025. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

Rhythm Biosciences's Payments of Debt for the six months ended in Dec. 2025 was €-0.59 Mil.

Rhythm Biosciences's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.59 Mil.

Rhythm Biosciences Payments of Debt Related Terms

Rhythm Biosciences Payments of Debt Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences Payments of Debt Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Payments of Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -0.65

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.70 0.00 -0.59
FRA:0RY
31GF Score
Rhythm Biosciences Ltd FRA:0RY
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Biosciences Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €-0.59 Mil mean?
Rhythm Biosciences (FRA:0RY) has a Payments of Debt of €-0.59 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Rhythm Biosciences and its competitors.
Is Rhythm Biosciences' Payments of Debt too high?
Rhythm Biosciences' current Payments of Debt is €-0.59 Mil. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Payments of Debt compare to TMO and DHR?
Rhythm Biosciences' Payments of Debt of €-0.59 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Diagnostics & Research company?
A good Payments of Debt depends on the Medical Diagnostics & Research industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Rhythm Biosciences and its competitors. Rhythm Biosciences's current Payments of Debt is €-0.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Payments of Debt of €-0.59 Mil. The current Payments of Debt is €-0.59 Mil. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Payments of Debt is €-0.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Other Exchanges RHY:Australia
Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score

Get the complete analysis for FRA:0RY

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price